

We claim:

- 134 ~~sub~~ 1. A protease ~~inhibitor~~ comprising two or more transition-state isosteres.
2. The inhibitor of claim 1 wherein the transition-state isostere is -CH(OH)-CH₂-.
- ~~13~~ 3. The inhibitor of claim 1 wherein the protease inhibitor inhibits an aspartic acid protease.
- 134 ~~sub~~ 4. The inhibitor of claim 3 wherein the protease inhibitor inhibits HIV protease.
- c1 ~~sub~~ 5. The inhibitor of claim 1 which is UIC-98-056.
6. The inhibitor of claim 2 wherein the CH(OH)-CH₂ is substituted with two other kinds of isosteres.
- 134 ~~sub~~ 7. A method for treating a patient infected with a pathogen expressing a protease comprising administering a protease inhibitor comprising two or more transition-state isosteres.
8. The method of claim 7 wherein the transition-state isostere is CH(OH)-CH₂-.
- ~~13~~ 9. The method of claim 7 wherein the protease inhibitor inhibits an aspartic acid protease.
- 134 ~~sub~~ 10. The method of claim 9 wherein the protease inhibitor inhibits HIV protease.
- c ~~sub~~ 11. The method of claim 10 wherein the inhibitor is UIC-98-056.
12. The method of claim 8 wherein the CH(OH)-CH₂ is substituted with two other kinds of isosteres.